Today only on the entire range
02:14:33
Library
Recent research
The newest published studies on research peptides, with direct links to the source. Updated as new studies appear.
This multicentre, double-blind, placebo-controlled phase 3 study evaluated thymosin alpha 1 in adults with sepsis.
The efficacy and safety of thymosin a1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial ↗This phase 2a study investigated the effect of retatrutide on liver fat in patients with metabolic dysfunction-associated steatotic liver disease.
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial ↗Open-label follow-up study (TAZPOWER) on elamipretide in patients with Barth syndrome.
Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER ↗- nad+
Randomised, placebo-controlled clinical study on nicotinamide riboside in older adults with mild cognitive impairment.
A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment ↗ - Semaglutide
This study (SELECT) investigated cardiovascular outcomes of semaglutide in people with obesity and established cardiovascular disease without diabetes.
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes ↗ - Tirzepatide
This phase 3 study (SURMOUNT-2) investigated the effect of weekly tirzepatide on weight in people with obesity and type 2 diabetes.
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) ↗ This phase 2 study investigated the effect of the triple-receptor agonist retatrutide on body weight in adults with obesity.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial ↗This phase 2 study investigated the efficacy of retatrutide on blood glucose and weight in people with type 2 diabetes.
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a phase 2 trial ↗Randomised phase 3 clinical study (MMPOWER-3) on elamipretide in individuals with primary mitochondrial myopathy.
Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial ↗- nad+
Randomised, placebo-controlled clinical study on the safety and NAD+-raising action of NMN supplementation in healthy middle-aged adults.
The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, dose-dependent clinical trial ↗ Animal research in rats studied BPC-157 in an incisional pain model.
The anti-nociceptive effect of BPC-157 on the incisional pain model in rats ↗- Tirzepatide
This phase 3 study (SURMOUNT-1) investigated the effect of weekly tirzepatide on body weight in adults with obesity without diabetes.
Tirzepatide Once Weekly for the Treatment of Obesity ↗ This phase 1b study investigated the safety, pharmacokinetics, and initial effects of retatrutide (LY3437943) in people with type 2 diabetes.
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b trial ↗Mouse-model research on the effect of MOTS-c on cardiac tissue under pressure-overload conditions.
Mitochondrial derived peptide MOTS-c prevents the development of heart failure under pressure overload conditions in mice ↗This clinical subgroup analysis of the RECONNECT phase 3 data examined bremelanotide across different age, weight, and BMI subgroups.
Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide ↗This analysis pooled the reported safety data of bremelanotide from 43 clinical studies within the full development programme.
Safety Profile of Bremelanotide Across the Clinical Development Program ↗- nad+
Randomised, placebo-controlled clinical study on nicotinamide riboside in relation to systolic blood pressure and arterial stiffness in middle-aged and older adults.
Nicotinamide Riboside Supplementation for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Midlife and Older Adults ↗ Animal research in rats studied BPC 157 in relation to the myotendinous junction after injury.
Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats ↗- Semaglutide
This phase 3 study (STEP 1) investigated the effect of weekly semaglutide 2.4 mg on body weight in adults with overweight or obesity without diabetes.
Once-Weekly Semaglutide in Adults with Overweight or Obesity ↗ - Semaglutide
This phase 3 study (STEP 2) investigated the effect of weekly semaglutide on weight in adults with overweight or obesity and type 2 diabetes.
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2) ↗ - Semaglutide
This phase 3 study (STEP 4) investigated whether continued weekly semaglutide versus placebo affected the maintenance of weight loss.
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial ↗ - Tirzepatide
This phase 3 study (SURPASS-1) investigated the efficacy and safety of tirzepatide as monotherapy in patients with type 2 diabetes.
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1) ↗ - Tirzepatide
This phase 3 study (SURPASS-2) compared weekly tirzepatide with semaglutide in patients with type 2 diabetes.
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes ↗ Animal study investigating how MOTS-c is regulated by exercise and is associated with age-related changes in muscle function in mice.
MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis ↗
For laboratory and research use only. Not for human or animal consumption, diagnostics or therapeutic use.